CL2017003112A1 - Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo. - Google Patents

Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo.

Info

Publication number
CL2017003112A1
CL2017003112A1 CL2017003112A CL2017003112A CL2017003112A1 CL 2017003112 A1 CL2017003112 A1 CL 2017003112A1 CL 2017003112 A CL2017003112 A CL 2017003112A CL 2017003112 A CL2017003112 A CL 2017003112A CL 2017003112 A1 CL2017003112 A1 CL 2017003112A1
Authority
CL
Chile
Prior art keywords
azetidin
acetonitrile
processes
preparation
ethylsulfonyl
Prior art date
Application number
CL2017003112A
Other languages
English (en)
Inventor
Michael Edward Kobierski
Michael E Kopach
Joseph R Martinelli
David Lee Varie
Thomas Michael Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56204068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003112(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2017003112A1 publication Critical patent/CL2017003112A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>PROCESOS E INTERMEDIARIOS PARA LA PREPARACIÓN DE {1-(ETILSULFONIL)-3-[4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL]AZETIDIN-3-IL}ACETONITRILO.</p>
CL2017003112A 2015-06-19 2017-12-05 Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo. CL2017003112A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562182040P 2015-06-19 2015-06-19

Publications (1)

Publication Number Publication Date
CL2017003112A1 true CL2017003112A1 (es) 2018-06-01

Family

ID=56204068

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003112A CL2017003112A1 (es) 2015-06-19 2017-12-05 Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo.

Country Status (26)

Country Link
US (2) US20180134713A1 (es)
EP (1) EP3310781A1 (es)
JP (1) JP2018519280A (es)
KR (1) KR20180008637A (es)
CN (1) CN107660206A (es)
AR (1) AR104918A1 (es)
AU (1) AU2016280815A1 (es)
BR (1) BR112017024613A2 (es)
CA (1) CA2984627A1 (es)
CL (1) CL2017003112A1 (es)
CO (1) CO2017013226A2 (es)
CR (1) CR20170533A (es)
DO (1) DOP2017000300A (es)
EA (1) EA201792308A1 (es)
EC (1) ECSP17083426A (es)
HK (1) HK1248699A1 (es)
IL (1) IL255386A0 (es)
MA (1) MA45901A (es)
MX (1) MX2017015837A (es)
NZ (1) NZ736999A (es)
PE (1) PE20180504A1 (es)
PH (1) PH12017502360A1 (es)
SV (1) SV2017005586A (es)
TN (1) TN2017000530A1 (es)
TW (1) TWI622591B (es)
WO (1) WO2016205487A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108341818A (zh) * 2017-01-21 2018-07-31 南京华威医药科技开发有限公司 巴瑞克替尼及其磷酸盐的新晶型及其制备方法
CA3055233C (en) 2017-01-23 2022-08-09 Shanghai Longwood Biopharmaceuticals Co., Ltd. Jak kinase inhibitor and preparation method and use thereof
CN106946917B (zh) * 2017-03-20 2019-06-11 杭州科巢生物科技有限公司 一种jak抑制剂巴瑞替尼及其中间体的新合成方法
CN107739328B (zh) * 2017-11-22 2020-03-20 海化生命(厦门)科技有限公司 用于合成巴瑞替尼的关键中间体1的制备方法
CN108129482A (zh) * 2017-12-13 2018-06-08 江苏中邦制药有限公司 一种巴瑞替尼的制备方法
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
WO2020072870A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Co-crystal forms of baricitinib
TW202033198A (zh) 2018-10-17 2020-09-16 美商美國禮來大藥廠 以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
US11548895B2 (en) 2019-04-24 2023-01-10 Elanco Us Inc. Process for making crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile
US20250041304A1 (en) 2021-07-30 2025-02-06 Eli Lilly And Company Treatment of Hand Eczema with Baricitinib
CN117720543A (zh) * 2023-12-13 2024-03-19 东北林业大学 一种巴瑞替尼的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821374A (en) * 1995-11-21 1998-10-13 Hoffmann-La Roche Inc. Process for the oxidation of alcohols
HUE029767T2 (en) * 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
KR20130094710A (ko) * 2010-04-14 2013-08-26 어레이 바이오파마 인크. Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
CN102557901B (zh) * 2010-12-15 2014-06-11 上海医药工业研究院 6-氯己醛的制备方法
RS62867B1 (sr) * 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
CN105541891B (zh) * 2016-02-04 2017-11-28 东南大学 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法

Also Published As

Publication number Publication date
IL255386A0 (en) 2017-12-31
CR20170533A (es) 2018-01-25
NZ736999A (en) 2019-05-31
BR112017024613A2 (pt) 2018-07-31
SV2017005586A (es) 2018-04-24
AR104918A1 (es) 2017-08-23
TN2017000530A1 (en) 2019-04-12
TWI622591B (zh) 2018-05-01
KR20180008637A (ko) 2018-01-24
MX2017015837A (es) 2018-04-10
JP2018519280A (ja) 2018-07-19
PE20180504A1 (es) 2018-03-09
WO2016205487A1 (en) 2016-12-22
DOP2017000300A (es) 2018-01-31
AU2016280815A1 (en) 2017-11-23
US20190062337A1 (en) 2019-02-28
PH12017502360A1 (en) 2018-06-25
HK1248699A1 (zh) 2018-10-19
TW201712015A (zh) 2017-04-01
CO2017013226A2 (es) 2018-03-28
CN107660206A (zh) 2018-02-02
ECSP17083426A (es) 2018-02-28
US20180134713A1 (en) 2018-05-17
EP3310781A1 (en) 2018-04-25
CA2984627A1 (en) 2016-12-22
MA45901A (fr) 2019-06-19
EA201792308A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
CL2017003112A1 (es) Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo.
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu&#39;inhibiteurs de la kinase ret
MY184733A (en) Pyrimidine fgfr4 inhibitors
IL252983B (en) 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one as a seed treatment
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CL2016003145A1 (es) Compuestos de [1,2,4]triazol sustituido
HRP20171599T2 (hr) DERIVATI PIROLO[2,3-d]PIRIMIDINA KAO INHIBITORI JANUS KINAZA (JAK)
MX2019011789A (es) 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
EP3159340A4 (en) New bruton&#39;s tyrosine kinase inhibitor
MX388026B (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
EP3508487A4 (en) PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND
EP3096762C0 (en) PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS
EP3512951A4 (en) INNOVATIVE PARATRANSGENIC SYSTEM FOR THE BIOLOGICAL CONTROL OF DISEASE-RELATING MOSCITOS
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu&#39;inhibiteurs de pde2
HK1249756A1 (zh) 用於治疗疾病的稠合双环化合物
EP3323828A4 (en) ANTIBODIES FOR DETERMINING THE SEX OF SPERMA AND USE THEREOF
EP3104712A4 (en) Improved process for the synthesis of substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima
HK40037119A (en) Pyrimidine compounds useful as tyrosine kinase inhibitors
EP3727387A4 (en) PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
HK40028172A (en) Use of 4-bora-3a,4a-diaza-s-indacenes for the production of fluorescent fibres
MA46463A (fr) Composés de pyrazolo[1,5-a]pyridine substitués en tant qu&#39;inhibiteurs de la kinase ret
TH1501006629A (th) อนุพันธ์พีร์โรโล[2,3-d]ไพริมิดีนในฐานะอะกอนิสต์ของ CB2 รีเซปเตอร์